银诺医药-B(02591)在澳大利亚完成依苏帕格鲁肽α用于治疗肥胖和超重的II期临床试验的首例患者给药

Core Viewpoint - The company has initiated the first patient dosing in a Phase II clinical trial for Isunaprevir α aimed at treating obesity and overweight in Australia, with an expected enrollment of approximately 200 participants [1] Group 1 - The company is conducting a Phase II clinical trial for Isunaprevir α [1] - The trial is focused on treating obesity and overweight [1] - The first patient dosing occurred on August 25, 2025 [1] Group 2 - The trial is expected to enroll around 200 participants [1]